GAO Criticizes FDA for Allowing Momenta Scientist to Assist Agency

The Government Accountability Office (GAO) is criticizing the FDA for allowing a scientist from Momenta Pharmaceuticals to voluntarily assist the agency during its handling of the tainted heparin crisis in 2008. In a recent report, the GAO says that the FDA failed to consider that allowing Momenta to help with the crisis while still awaiting action on its generic version of Sanofi-Aventis’ blood-thinner Lovenox (enoxaparin sodium), a low-molecular weight heparin, could “undermine the public perception of FDA’s management of the heparin crisis.”
Washington Drug Letter